[HTML][HTML] Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines
Highlights•Understanding the existing drug repositioning methods with a top-down
flowchart.•Prioritizing repositioning methods using their integrated knowledge and …
flowchart.•Prioritizing repositioning methods using their integrated knowledge and …
[PDF][PDF] Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines
G Jin, STC Wong - cyberleninka.org
Recycling old drugs, rescuing shelved drugs and extending patents' lives make drug
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines
G Jin, STC Wong - Drug Discovery Today, 2014 - infona.pl
Recycling old drugs, rescuing shelved drugs and extending patents' lives make drug
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
[PDF][PDF] Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines
G Jin, STC Wong - Drug Discovery Today, 2014 - core.ac.uk
Recycling old drugs, rescuing shelved drugs and extending patents' lives make drug
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines
G Jin, STC Wong - Drug discovery today, 2014 - pubmed.ncbi.nlm.nih.gov
Recycling old drugs, rescuing shelved drugs and extending patents' lives make drug
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
[HTML][HTML] Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines
G Jin, STC Wong - Drug discovery today, 2014 - ncbi.nlm.nih.gov
Recycling old drugs, rescuing shelved drugs and extending patents' lives make drug
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
[PDF][PDF] Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines
G Jin, STC Wong - Drug Discovery Today, 2014 - researchgate.net
Recycling old drugs, rescuing shelved drugs and extending patents' lives make drug
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
[引用][C] Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines
G Jin, STC Wong - Drug Discovery Today, 2014 - cir.nii.ac.jp
Toward better drug repositioning: prioritizing and integrating existing methods into efficient
pipelines | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
pipelines | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.
G Jin, ST Wong - Drug Discovery Today, 2013 - europepmc.org
Recycling old drugs, rescuing shelved drugs and extending patents' lives make drug
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
repositioning an attractive form of drug discovery. Drug repositioning accounts for …
[PDF][PDF] Toward better drug repositioning: Prioritizing and integrating existing methods into efficient pipelines
G Jin, STC Wong - researchgate.net
A repositioned drug does not need the initial 6-9 years typically required for developing new
drugs, but goes directly to preclinical testing and clinical trials, thus reducing risk and costs …
drugs, but goes directly to preclinical testing and clinical trials, thus reducing risk and costs …